Chronic viral liver disease may evolve to cirrhosis. The medical treatment to slow down this passage is based on anti-viral and anti-fibrotic properties of interferon. Recently, we evidenced significant increase ofportal vein flow velocity and volume after a prostacyclin analog (iloprost) infusion in subjects without and withchronic viral hepatitis. On the basis of these results and considering both the pathophysiology of viral liverdisease and the mechanism of action of iloprost in portal microcirculation, we hypothesize that it may be ofsome efficacy in chronic liver disease ameliorating the portal hemodynamics and producing an anti-oxidant liver effect.
Iloprost: an adjunctive approach to chronic viral hepatitis treatment
Zardi EM;Vespasiani Gentilucci U;Picardi A;Fazio VM;Dobrina A;Afeltra A
2005-01-01
Abstract
Chronic viral liver disease may evolve to cirrhosis. The medical treatment to slow down this passage is based on anti-viral and anti-fibrotic properties of interferon. Recently, we evidenced significant increase ofportal vein flow velocity and volume after a prostacyclin analog (iloprost) infusion in subjects without and withchronic viral hepatitis. On the basis of these results and considering both the pathophysiology of viral liverdisease and the mechanism of action of iloprost in portal microcirculation, we hypothesize that it may be ofsome efficacy in chronic liver disease ameliorating the portal hemodynamics and producing an anti-oxidant liver effect.I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
